Balefire LLC Invests $376,000 in United Therapeutics in Q2

Summary

Balefire LLC invested $376,000 in United Therapeutics Corporation by acquiring 1,307 shares during the 2nd quarter, as reported in their recent 13F filing. Other hedge funds have also adjusted their stakes in the company. CEO Martine A. Rothblatt and COO Michael Benkowitz sold significant shares recently. Analysts have raised price targets for UTHR, with UBS setting a target of $560. The stock opened at $403.68, with a market cap of $18.21 billion and a P/E ratio of 15.76.Market Beat

Impact Analysis

So basically, Balefire LLC’s $376,000 investment in United Therapeutics (UTHR) is intriguing given the backdrop of insider selling and mixed analyst ratings. While the CEO and COO offloaded shares, UBS has raised its price target to $560, suggesting some confidence in the company’s prospects despite the insider activity Market Beat. The stock’s current P/E ratio of 15.76 and a market cap of $18.21 billion indicate it’s not overly expensive, which might be why Balefire sees value here. The interesting part isn’t just the investment itself, but the timing—amidst a period where other hedge funds are also adjusting their stakes. This could signal a belief in UTHR’s long-term potential, possibly driven by its focus on pulmonary arterial hypertension treatments, which have shown strong revenue performance Stock Star+ 2. Market’s missing that this might be a strategic entry point before potential upside materializes. Watching how other institutional investors move next could provide further clues.